Bausch + Lomb Acquires Elios Vision to Expand Glaucoma Solutions

In a strategic move to refine glaucoma treatment, Bausch + Lomb has acquired Elios Vision Inc., signaling a potential breakthrough in eye health technology. The global eye care giant has secured the innovative ELIOS procedure, positioning itself at the cutting edge of minimally invasive surgical solutions.

Luc Bonnefoy, President of Bausch + Lomb’s Surgical Division emphasized the significance of this addition: “The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47% from 2020 to 2040,” he stated in the news release. 

But what exactly makes the ELIOS procedure so revolutionary?

Breakthrough Technology: The ELIOS Procedure Explained

The ELIOS procedure is a minimally invasive glaucoma surgery (MIGS) designed to lower intraocular pressure (IOP) in patients with glaucoma. It involves creating microchannels in the eye’s trabecular meshwork to enhance the natural outflow of aqueous humor, reducing pressure buildup that can damage the optic nerve. Through advanced laser technology, the ELIOS procedure aims to provide effective pressure relief with minimal tissue disruption, offering a safer and less invasive alternative to traditional glaucoma surgeries.

What Are the Advantages of the ELIOS System?

• Minimally Invasive Procedure: The ELIOS system employs a non-thermal excimer laser to create precise microchannels in the trabecular meshwork, facilitating aqueous humor outflow and reducing intraocular pressure (IOP) without significant tissue damage.
• Implant-Free Approach: Unlike other MIGS procedures that require implants, the ELIOS system achieves effective IOP reduction without leaving any foreign material in the eye, potentially reducing long-term complications.
• Compatibility with Cataract Surgery: The ELIOS procedure can be easily performed in conjunction with cataract surgery, offering a more organized approach for patients requiring both treatments and potentially improving overall surgical outcomes.
• Favorable Safety Profile: Clinical studies have demonstrated that the ELIOS system effectively lowers IOP with a low incidence of complications, making it a safe option for glaucoma patients.
• Long-Lasting Results: Research indicates that the IOP-lowering effects of the ELIOS procedure are sustained over time, with some studies reporting effectiveness lasting up to 8 years.

These advantages position the ELIOS system as a promising option in the management of glaucoma, providing patients with a less invasive and effective treatment alternative.

Clinical Validation and Adoption

The ELIOS procedure has gained traction in Europe, where it holds CE marking and has been utilized in thousands of cases. Clinical studies have demonstrated its efficacy and safety, with long-term follow-ups indicating sustained IOP reduction and favorable outcomes. 

Notably, a study published in Graefe’s Archive for Clinical and Experimental Ophthalmology reported an 8-year follow-up of patients undergoing combined phacoemulsification and ELIOS, highlighting the procedure’s durability and effectiveness.

Regulatory Status and Future Prospects

While the ELIOS system is currently CE-marked and available in the European Union, efforts are underway to secure FDA approval for the U.S. market. Elios Vision has completed enrollment for its U.S. clinical trial, involving over 300 patients with mild to moderate glaucoma treated in combination with cataract surgery. The results of this trial will be instrumental in determining the procedure’s future availability in the United States.

Our Take at Lens.com

Bausch + Lomb’s acquisition of Elios Vision and its ELIOS system is a big win for glaucoma treatment. The ELIOS system offers a minimally invasive, tissue-preserving alternative to traditional surgical methods, which could change the game for many patients. 

This move adds even more depth to Bausch + Lomb’s already impressive product lineup and reinforces their role as a leader in eye health. It also shows their dedication to keeping up with the rapidly changing needs of patients and eye care professionals. 

Through innovative, patient-first solutions, Bausch + Lomb is raising the bar in ophthalmology.